0RN4 Stock Overview A biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Oncopeptides AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Oncopeptides Historical stock prices Current Share Price SEK 1.51 52 Week High SEK 7.80 52 Week Low SEK 1.49 Beta -0.34 1 Month Change -0.59% 3 Month Change -28.46% 1 Year Change -80.52% 3 Year Change -81.49% 5 Year Change -98.80% Change since IPO -96.71%
Recent News & Updates
Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.45 loss in 3Q 2023) Nov 08
New minor risk - Share price stability Nov 07
Second quarter 2024 earnings released: kr0.48 loss per share (vs kr0.60 loss in 2Q 2023) Aug 19
An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million. Jul 04
First quarter 2024 earnings released: kr0.75 loss per share (vs kr0.75 loss in 1Q 2023) Jun 04
Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress May 17 See more updates
Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.45 loss in 3Q 2023) Nov 08
New minor risk - Share price stability Nov 07
Second quarter 2024 earnings released: kr0.48 loss per share (vs kr0.60 loss in 2Q 2023) Aug 19
An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million. Jul 04
First quarter 2024 earnings released: kr0.75 loss per share (vs kr0.75 loss in 1Q 2023) Jun 04
Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress May 17
New major risk - Shareholder dilution May 08
New minor risk - Shareholder dilution Apr 08 Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024 Apr 04
Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million. Mar 13
New major risk - Financial position Feb 28
Oncopeptides AB (publ), Annual General Meeting, May 22, 2024 Feb 24
Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines Dec 16
Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024 Nov 18
Oncopeptides Selects to Present Additional Data from Ocean Study Nov 15
New major risk - Financial position Nov 09
Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024 Oct 27
Oncopeptides AB (publ) Announces the Nomination Committee Oct 21
Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024 Oct 12
Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024 Oct 02
Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024 Sep 21
Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results Sep 15
Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial Officer Aug 10 Oncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO Role
Holger Lembrér Will Leave Oncopeptides as Chief Financial Officer Jun 14
No longer forecast to breakeven May 09 Oncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023
Full year 2022 earnings released: kr4.11 loss per share (vs kr19.00 loss in FY 2021) Feb 17
Forecast to breakeven in 2024 Feb 12
Oncopeptides AB (Publ) Announces Chief Financial Officer Changes Jan 12
Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific Officer Jan 05
Oncopeptides AB (Publ) Announces Executive Changes Jan 04
Oncopeptides AB (publ) Announces Nomination Committee Appointments Dec 23
Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023 Dec 15
Oncopeptides Provides Update on Pepaxto US Marketing Authorization Dec 08
Insufficient new directors Nov 16
Oncopeptides AB (Publ) Announces Pepaxti Has Been Granted Marketing Authorization in the Uk Nov 12
Oncopeptides AB (Publ) Announces the Market Potential for Pepaxti in Europe Nov 11
Forecast to breakeven in 2024 Nov 10
Oncopeptides AB (publ), Annual General Meeting, May 25, 2023 Nov 09
Oncopeptides AB (publ) Announces Data from the Phase 3 Lighthouse Study Oct 26
Oncopeptides AB (publ) Starts Commercialization of Pepaxti in Europe - Germany First Market Oct 04
Oncopeptides AB (publ) Provides Update from Meeting with Advisory Committee ODAC Sep 23
Oncopeptides AB (Publ) Receives SEK 5 Million Grant for Nk-Cell Engager Project in Multiple Myeloma Sep 08
European Commission Approves Oncopeptides' Pepaxti for the Treatment of Patients with Relapsed Refractory Multiple Myeloma Aug 19
Second quarter 2022 earnings released: kr0.79 loss per share (vs kr0.32 loss in 2Q 2021) Aug 12
Forecast to breakeven in 2024 Aug 12
Now 31% undervalued Jun 28
Oncopeptides AB (Publ) Issues A Positive Opinion Recommending Full Approval of Oncopeptides Peti in Eu for Patients with Tr Triple Class Refractory Multiple Myeloma Jun 25
Oncopeptides AB (Publ) Announces That the European Medicines Agency´S Committee for Medicinal Products for Human Use Jun 24
First quarter 2022 earnings released: kr1.31 loss per share (vs kr3.45 loss in 1Q 2021) May 06
No longer forecast to breakeven Apr 27
Insufficient new directors Apr 27
Chief Executive Officer recently bought kr2.0m worth of stock Feb 20
Oncopeptides AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023 Feb 18
No longer forecast to breakeven Feb 17
Oncopeptides Rescinds Voluntary Withdrawal of Pepaxto in the US – No Intent to Market in the US at This Time Jan 22
Independent Chairman of the Board recently bought kr1.4m worth of stock Jan 14
Oncopeptides AB (Publ) Announces Data from Phase 3 Ocean Study Published in the Lancet Haematology Jan 13
Insufficient new directors Jan 02
Chief Executive Officer Martin Duvall has left the company Nov 28
Chief Executive Officer Martin Duvall has left the company Nov 28
Chief Executive Officer Martin Duvall has left the company Nov 28
Chief Executive Officer Martin Duvall has left the company Nov 28
Chief Executive Officer Martin Duvall has left the company Nov 28
Chief Executive Officer Martin Duvall has left the company Nov 28
Chief Executive Officer Martin Duvall has left the company Nov 28
Chief Executive Officer Martin Duvall has left the company Nov 28
Chief Executive Officer Martin Duvall has left the company Nov 28
Chief Executive Officer Martin Duvall has left the company Nov 28
Chief Executive Officer Martin Duvall has left the company Nov 28
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 27
Chief Executive Officer Martin Duvall has left the company Nov 26
Chief Executive Officer Martin Duvall has left the company Nov 26
Chief Executive Officer Martin Duvall has left the company Nov 26
Chief Executive Officer Martin Duvall has left the company Nov 26
Chief Executive Officer Martin Duvall has left the company Nov 26
Chief Executive Officer Martin Duvall has left the company Nov 26 Shareholder Returns 0RN4 GB Biotechs GB Market 7D -3.0% -5.0% -1.9% 1Y -80.5% -24.4% 2.6%
See full shareholder returns
Return vs Industry: 0RN4 underperformed the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: 0RN4 underperformed the UK Market which returned 2.4% over the past year.
Price Volatility Is 0RN4's price volatile compared to industry and market? 0RN4 volatility 0RN4 Average Weekly Movement 8.8% Biotechs Industry Average Movement 6.9% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0RN4's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RN4's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors.
Show more Oncopeptides AB (publ) Fundamentals Summary How do Oncopeptides's earnings and revenue compare to its market cap? 0RN4 fundamental statistics Market cap SEK 319.34m Earnings (TTM ) -SEK 282.39m Revenue (TTM ) SEK 27.07m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0RN4 income statement (TTM ) Revenue SEK 27.07m Cost of Revenue SEK 2.72m Gross Profit SEK 24.35m Other Expenses SEK 306.75m Earnings -SEK 282.39m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.31 Gross Margin 89.96% Net Profit Margin -1,043.15% Debt/Equity Ratio 86.4%
How did 0RN4 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 14:04 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Oncopeptides AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Erik Hultgård Carnegie Investment Bank AB Patrik Ling DNB Markets Robert Burns H.C. Wainwright & Co.
Show 4 more analysts 
